Allogene Therapeutics, Inc. IPO Research Information

Allogene Therapeutics, Inc. IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on Allogene Therapeutics, Inc. , and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
Allogene Therapeutics, Inc.	ALLO - NASDAQ	$16.00-$18.00	$18.00	$22.00	18 million	10/11/2018
Underwriter(s): Goldman Sachs & Co, J.P. Morgan, Cowen, Jefferies
Co-Manager(s):
Industry: Health Care
Filing(s): Filed 2018-09-14 Terms Added 2018-10-02

Allogene Therapeutics, Inc. Quote & Chart - Click for current quote - ALLO

About Allogene Therapeutics, Inc. (adapted from Allogene Therapeutics, Inc. prospectus):
They are a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "ALLO" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.